Roflumilast

02/01/2014 - "A significant reduction in COPD exacerbation risk with roflumilast vs. placebo was observed regardless of age or smoking status, and in patients who had severe or very severe COPD. "
01/01/2014 - "The addition of roflumilast to LABA in the treatment of patients with severe-to-very severe COPD reduces the rate of exacerbations and can be cost-effective in the UK setting."
12/01/2013 - "Roflumilast is a safe and effective option for controlling COPD exacerbations in a defined subset of patients for whom the available treatment alternatives are very limited."
01/01/2007 - "Roflumilast has the potential to be cost saving in patients with very severe COPD, due to a statistically significant reduction of exacerbations."
01/01/2016 - "A recent meta-analysis of trials on COPD revealed that treatment with roflumilast was associated with a significant reduction in the rate of major cardiovascular events. "

12/01/2015 - "To evaluate the therapeutic efficacy and mechanism of action of roflumilast in patients with asthma using data from eight placebo-controlled, double-blind phase I-III studies. "
01/01/2016 - "We evaluated the potential of roflumilast as a novel therapeutic agent for obese subjects with asthma. "
12/01/2015 - "A series of placebo-controlled trials were undertaken in order to investigate the safety and efficacy of roflumilast in asthma. "
01/01/2021 - "However, the clinical trials of roflumilast in severe asthma have been limited. "
12/01/2015 - "Roflumilast for asthma: Safety findings from a pooled analysis of ten clinical studies."

08/01/2023 - "Roflumilast is effective and safe for the treatment of plaque psoriasis and intertriginous psoriasis. "
09/01/2022 - "Killing all the birds with one drug - is oral roflumilast a novel treatment option for psoriasis?"
01/01/2023 - "Two phase 3 clinical trials have demonstrated the efficacy of once daily application of roflumilast to treat plaque psoriasis in patients aged 12 years and older. "
01/01/2022 - "To evaluate the efficacy of roflumilast cream, 0.3%, applied once daily for 8 weeks in 2 trials of patients with plaque psoriasis. "
03/01/2023 - "Roflumilast cream improved itch and itch-related sleep loss associated with chronic plaque psoriasis. "

08/01/2017 - "These results indicate that roflumilast is effective in treating cerebral inflammation following SAH."
08/01/2017 - "This study investigates the effects of roflumilast on cerebral inflammation in the rat SAH model. "
01/01/2015 - "The aim of this study was to evaluate the effect of long-term administration of roflumilast in experimental allergic inflammation in guinea pigs. "
10/01/2010 - " The available long-term clinical studies reviewed here suggest that the clinical efficacy of roflumilast is likely because of the suppression of airway inflammation and not through bronchodilation. "
07/20/2022 - "Roflumilast has been shown to alleviate inflammatory responses, thus regulating airway inflammation. "

01/01/2023 - "We explored the value of maintaining cognition in patients with mild cognitive impairment (MCI) by estimating: (1) the innovation headroom and (2) the potential cost effectiveness of roflumilast treatment in this population. "
01/01/2023 - "The value of maintaining cognition in patients with mild cognitive impairment: The innovation headroom and potential cost-effectiveness of roflumilast."
01/01/2023 - "Roflumilast has shown an anti-neuroinflammatory effect and reversed the cognitive decline in LPS-induced mice model."
12/10/2020 - "In the novel object recognition and Morris water-maze, APPswe/PS1dE9 mice showed significant cognitive declines, which were reversed by roflumilast at 5 and 10 mg/kg orally once per day. "
01/01/2020 - "Roflumilast: A potential drug for the treatment of cognitive impairment?"